Navigation Links
Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
Date:1/14/2009

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is seeking to obtain two new drug approvals in 2009 in addition to potential label expansion for Zevalin(R). In November CTI established a 50/50 joint venture with Spectrum Pharmaceuticals, Inc. (Spectrum) for Zevalin.

"With a focus on cutting-edge oncology drug products, CTI aims to complete its transition from a research-based organization to a leading commercial oncology company," said James A. Bianco, M.D., CEO of Cell Therapeutics. "In 2008 we set the stage for becoming a multi-product commercial oncology operating company, with Zevalin currently under priority review by the FDA in the U.S. for label expansion, OPAXIO(TM) under review for market authorization application approval in Europe and, based on positive Phase III data for pixantrone, we expect to file a rolling NDA in 2009. Additionally, we continue to focus on improving our capital structure, streamlining our operations and significantly reducing our cash burn rate. With potential approval of pixantrone and OPAXIO in 2009, and potential sales revenue growth due to possible Zevalin label expansion, we are on target to accomplish our goal of reaching cashflow break-even in the fourth quarter of 2009," Bianco added.

Targeted 2009 Milestones:

ZEVALIN -- First- line consolidation indication approval for Zevalin with a target decision date by the FDA of April 2, 2009, based on a supplemental biologics license application (sBLA) submitted on October 2, 2008 for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. CTI and Spectrum have a joint venture for the sales, marketing and development of Z
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Oregon , July 29, 2014 ... "Global surgical equipment market (types, applications and geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... to reach $12.1 billion by 2020 registering a CAGR ... to the breakthrough achieved by the electro surgical devices ...
(Date:7/29/2014)... Hershey, PA & Rockville, MD (PRWEB) July 29, ... Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in ... the financial services firm Newport Coast Securities, Inc. ... , ITI is commercializing LAMP-vax technology, a breakthrough ... $25B+ vaccines and immunotherapy market. The company exclusively ...
(Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
(Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... discovery of two additional coral communities showing signs of damage ... of the 2010 spill in the Gulf of Mexico. The ... professor of biology at Penn State University. A paper describing ... in the Gulf of Mexico will be published during the ... of the journal Proceedings of the National Academy of ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... it may be more lyrical than useful when discussing ... of the Sackler Institute of Comparative Genomics at the ... the University of Colorado at Boulder. The team used ... the populations of small mammals living on mountaintops in ...
... on a nano scale how can you see what you ... Biological Sciences research Council (BBSRC) fellow has made a significant ... With new research published today (13 August) in ... School of Pharmacy (University of London) and the University of ...
... also available in German . Halle/Saale, ... plant species could lose parts of its current range, ... Environmental Research (UFZ), the Potsdam Institute for Climate Impact ... Species distributions will be rearranged as a result of ...
Cached Biology News:Sky islands: metaphor or misnomer? 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3Climate change threatens 1 in 5 plant species 2
Prepared in distilled water....
... RiboGreen RNA Quantitation Kit is one ... for the quantitation of RNA in ... 1000-fold more sensitive than absorbance measurements. ... be detected with fluorescence microplate readers ...
Request Info...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: